Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) Stock Competitors & Peer Comparison
See KNSA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for KNSA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KNSA | $78.08 | -0.76% | 6.1B | 88.67 | $0.90 | N/A |
| RPRX | $60.85 | -1.73% | 27B | 11.59 | $5.25 | +1.52% |
| CORT | $113.88 | -2.61% | 12.3B | 325.37 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $67.69 | -3.22% | 6B | 483.50 | $0.14 | N/A |
| PBH | $52.47 | +2.46% | 2.5B | 11.87 | $4.42 | N/A |
| LTGO | $24.23 | -3.08% | 1.5B | N/A | N/A | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| HELP | $12.18 | -8.01% | 755M | -2.92 | -$4.16 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
KNSA vs RPRX Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, RPRX has a market cap of 27B. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while RPRX trades at $60.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas RPRX's P/E ratio is 11.59. In terms of profitability, KNSA's ROE is +0.14%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, KNSA is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
KNSA vs CORT Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while CORT trades at $113.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas CORT's P/E ratio is 325.37. In terms of profitability, KNSA's ROE is +0.14%, compared to CORT's ROE of +0.08%. Regarding short-term risk, KNSA is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
KNSA vs WBA Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas WBA's P/E ratio is -1.64. In terms of profitability, KNSA's ROE is +0.14%, compared to WBA's ROE of -0.42%. Regarding short-term risk, KNSA is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
KNSA vs LQDA Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, LQDA has a market cap of 6B. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while LQDA trades at $67.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas LQDA's P/E ratio is 483.50. In terms of profitability, KNSA's ROE is +0.14%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, KNSA is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
KNSA vs PBH Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, PBH has a market cap of 2.5B. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while PBH trades at $52.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas PBH's P/E ratio is 11.87. In terms of profitability, KNSA's ROE is +0.14%, compared to PBH's ROE of +0.09%. Regarding short-term risk, KNSA is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check PBH's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
KNSA vs LTGO Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, LTGO has a market cap of 1.5B. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while LTGO trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas LTGO's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to LTGO's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check LTGO's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
KNSA vs HROWL Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas HROWL's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, KNSA is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
KNSA vs HROWM Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas HROWM's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, KNSA is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check HROWM's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
KNSA vs HELP Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, HELP has a market cap of 755M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while HELP trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas HELP's P/E ratio is -2.92. In terms of profitability, KNSA's ROE is +0.14%, compared to HELP's ROE of -0.71%. Regarding short-term risk, KNSA is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
KNSA vs SVA Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas SVA's P/E ratio is -5.68. In terms of profitability, KNSA's ROE is +0.14%, compared to SVA's ROE of -0.01%. Regarding short-term risk, KNSA is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
KNSA vs CUVL Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, CUVL has a market cap of 310.6M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while CUVL trades at $6.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas CUVL's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CUVL's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
KNSA vs CELG-RI Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, CELG-RI has a market cap of 244.7M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
KNSA vs HITI Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, HITI has a market cap of 220.6M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while HITI trades at $2.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas HITI's P/E ratio is -7.36. In terms of profitability, KNSA's ROE is +0.14%, compared to HITI's ROE of -0.43%. Regarding short-term risk, KNSA is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check HITI's competition here
Atlantic International Corp. (NASDAQ: ATLN)
KNSA vs ATLN Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas ATLN's P/E ratio is -0.68. In terms of profitability, KNSA's ROE is +0.14%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, KNSA is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
KNSA vs CTOR Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, CTOR has a market cap of 72.1M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while CTOR trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas CTOR's P/E ratio is -1.65. In terms of profitability, KNSA's ROE is +0.14%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, KNSA is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CTOR's competition here
Stablecoin Development Corp. (AMEX: SDEV)
KNSA vs SDEV Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, SDEV has a market cap of 47.8M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while SDEV trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas SDEV's P/E ratio is -0.17. In terms of profitability, KNSA's ROE is +0.14%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, KNSA is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
KNSA vs RAD Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas RAD's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to RAD's ROE of +2.76%. Regarding short-term risk, KNSA is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check RAD's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
KNSA vs NSRX Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, NSRX has a market cap of 34.9M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while NSRX trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas NSRX's P/E ratio is -5.62. In terms of profitability, KNSA's ROE is +0.14%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, KNSA is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check NSRX's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
KNSA vs GLTO Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas GLTO's P/E ratio is -1.78. In terms of profitability, KNSA's ROE is +0.14%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, KNSA is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check GLTO's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
KNSA vs SCYX Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, SCYX has a market cap of 34M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while SCYX trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas SCYX's P/E ratio is -1.58. In terms of profitability, KNSA's ROE is +0.14%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, KNSA is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SCYX's competition here
Cerenome, Inc. (NASDAQ: CNSY)
KNSA vs CNSY Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, CNSY has a market cap of 21M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while CNSY trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas CNSY's P/E ratio is -0.42. In terms of profitability, KNSA's ROE is +0.14%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, KNSA is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
KNSA vs BFRI Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, BFRI has a market cap of 20.4M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while BFRI trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas BFRI's P/E ratio is -2.89. In terms of profitability, KNSA's ROE is +0.14%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, KNSA is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BFRI's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
KNSA vs SCNX Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, SCNX has a market cap of 16M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while SCNX trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas SCNX's P/E ratio is -0.16. In terms of profitability, KNSA's ROE is +0.14%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, KNSA is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SCNX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
KNSA vs BFRIW Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, BFRIW has a market cap of 14.2M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, KNSA's ROE is +0.14%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, KNSA is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
KNSA vs COSM Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, COSM has a market cap of 12.2M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while COSM trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas COSM's P/E ratio is -0.30. In terms of profitability, KNSA's ROE is +0.14%, compared to COSM's ROE of -1.19%. Regarding short-term risk, KNSA is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check COSM's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
KNSA vs CJJD Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas CJJD's P/E ratio is -0.46. In terms of profitability, KNSA's ROE is +0.14%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, KNSA is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
KNSA vs SSY Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas SSY's P/E ratio is -2.86. In terms of profitability, KNSA's ROE is +0.14%, compared to SSY's ROE of -0.09%. Regarding short-term risk, KNSA is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
KNSA vs POM Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, POM has a market cap of 6.4M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while POM trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas POM's P/E ratio is -0.19. In terms of profitability, KNSA's ROE is +0.14%, compared to POM's ROE of +0.16%. Regarding short-term risk, KNSA is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
KNSA vs BGMS Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while BGMS trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas BGMS's P/E ratio is -0.25. In terms of profitability, KNSA's ROE is +0.14%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, KNSA is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BGMS's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
KNSA vs PAVS Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, PAVS has a market cap of 4.1M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while PAVS trades at $4.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas PAVS's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, KNSA is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
KNSA vs MDVL Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas MDVL's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, KNSA is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
KNSA vs ATNFW Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas ATNFW's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, KNSA is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
KNSA vs BGMSP Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, KNSA's ROE is +0.14%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, KNSA is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
KNSA vs AZNH Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas AZNH's P/E ratio is 38.35. In terms of profitability, KNSA's ROE is +0.14%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, KNSA is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
KNSA vs LFLYW Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, KNSA's ROE is +0.14%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, KNSA is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
KNSA vs PRPH Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, PRPH has a market cap of 295.7K. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while PRPH trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas PRPH's P/E ratio is -0.01. In terms of profitability, KNSA's ROE is +0.14%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, KNSA is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
KNSA vs CPD Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, CPD has a market cap of 0. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas CPD's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CPD's ROE of N/A. Regarding short-term risk, KNSA is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check CPD's competition here
POZEN Inc. (NASDAQ: POZN)
KNSA vs POZN Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, POZN has a market cap of 0. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas POZN's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to POZN's ROE of +0.61%. Regarding short-term risk, KNSA is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check POZN's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
KNSA vs ESRX Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas ESRX's P/E ratio is 10.69. In terms of profitability, KNSA's ROE is +0.14%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, KNSA is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check ESRX's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
KNSA vs OREX Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, OREX has a market cap of 0. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas OREX's P/E ratio is -0.14. In terms of profitability, KNSA's ROE is +0.14%, compared to OREX's ROE of -0.54%. Regarding short-term risk, KNSA is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check OREX's competition here
Shire plc (NASDAQ: SHPG)
KNSA vs SHPG Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas SHPG's P/E ratio is 11.35. In terms of profitability, KNSA's ROE is +0.14%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, KNSA is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check SHPG's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
KNSA vs IPXL Comparison September 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 6.1B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, KNSA is priced at $78.08 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 88.67, whereas IPXL's P/E ratio is -10.11. In terms of profitability, KNSA's ROE is +0.14%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, KNSA is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check IPXL's competition here